血小板受体GPVI作为抗血栓靶点的研究进展

发布时间：2018-01-31 15:25

本文关键词： 血小板糖蛋白Ⅵ 止血血栓抗血栓　出处：《中国实验血液学杂志》2017年01期 　论文类型：期刊论文

【摘要】：血小板活化是生理性止血中的关键步骤,在病理性血栓形成中也起着重要的作用。通过抑制血小板活化以预防和治疗血栓是血栓性疾病防治的重要手段之一。然而,目前临床抗血栓药物的高效性以出血风险增加为代价。血小板糖蛋白受体VI(GPVI)是血小板特异性受体,其与胶原的结合是血小板活化的关键。它作为一种新型抗血栓药物靶点,其拮抗剂能抑制血栓及其炎症反应,又不干扰正常止血机制,既安全又有效。本文对血小板GPVI的结构与功能,在出血和血栓形成中的作用及其拮抗剂的最新研究进展作一综述,并对未来开发出具有临床意义的以GPVI为靶点的抗血小板药物进行展望,以期为血栓栓塞性疾病提供可靠的药物治疗。
[Abstract]:Platelet activation is a key step in physiological hemostasis. It also plays an important role in the formation of pathological thrombus. Preventing and treating thrombus by inhibiting platelet activation is one of the important methods to prevent and treat thrombotic diseases. At present, the high efficiency of clinical antithrombotic drugs is at the expense of increased risk of bleeding. Platelet glycoprotein receptor VI- GPVI is a platelet-specific receptor. As a new antithrombotic target, its antagonist can inhibit thrombus and its inflammatory reaction without interfering with the normal hemostatic mechanism. In this review, the structure and function of platelet GPVI, its role in bleeding and thrombosis and its antagonist were reviewed. In order to provide reliable drug therapy for thromboembolic diseases, the future development of antiplatelet drugs with clinical significance with GPVI as the target is prospected.
【作者单位】：徐州医学院血液病研究所;
【基金】：国家自然科学基金(81400082) 江苏省自然科学基金(BK20140219)
【分类号】：R55
【正文快照】： 尽管血小板在生理性止血和病理性血栓形成进程中的分子机制的研究取得了重大进展,预防和减少出血与血栓性疾病发生仍然是临床面临的一大挑战。目前临床上广泛使用的抗血小板药物治疗的标准组合是阿司匹林与氯吡格雷或普拉格雷[1],这种治疗方案可有效的预防高危人群心血管疾病

【相似文献】